phrykt

Aspen Neuroscience, Inc. (ASPE): who owns it and who trades it

As of Nov 9, 2026, ASPE insiders reported 4 purchases worth $35M in the last 12 months. The largest buyer was ARCH Venture Fund X, L.P. (10% owner), with $20M.

Latest filing Nov 9, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

In the last 12 months, ASPE insiders reported $35M of open-market purchases and $0 of sales.

Purchases, 12 months
$35M
4 trades, 2 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Nov 2, 2026
Filed Nov 4, 2026

Purchases and sales by month

$35M$35MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 2, 2026Orbimed Advisors Llc +1DirectorPurchase1.00M$15.00$15MForm 4
Nov 2, 2026ARCH Venture Fund X, L.P. +810% ownerPurchase66,666$15.00$1000KForm 4
Nov 2, 2026ARCH Venture Fund X, L.P. +810% ownerPurchase66,667$15.00$1MForm 4
Nov 2, 2026ARCH Venture Fund X, L.P. +810% ownerPurchase1.20M$15.00$18MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
ARCH Venture Fund X, L.P.10% owner$20M–Nov 2, 2026
Orbimed Advisors LlcDirector, 10% owner$15M–Nov 2, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

Aspen Neuroscience company events

Aspen Neuroscience filed 1 report on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 2, 2026.

  1. Nov 2, 2026AnnouncementThe Company completed the IPO of 9,375,000 shares of the Company’s common stock, par value $0.0001 per share, at a price to the public of $15.00 per share. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 12 filings named ASPE in the last 120 days.

FiledHolderFormStake
Nov 9, 2026ARCH Venture Fund X, L.P.13D12.9%
Nov 9, 2026ARCH Venture Fund X, L.P.13D12.9%
Nov 9, 2026Frazier Life Sciences X, L.P.13G5.8%
Nov 9, 2026Frazier Life Sciences X, L.P.13G5.8%
Nov 6, 2026ORBIMED ADVISORS LLC13D12.3%
Nov 6, 2026ORBIMED ADVISORS LLC13D12.3%
Nov 6, 2026FMR LLC13G11.2%
Nov 6, 2026GILEAD SCIENCES, INC.13G9.9%
Nov 6, 2026FMR LLC13G11.2%
Nov 6, 2026GILEAD SCIENCES, INC.13G9.9%
Nov 3, 2026Qatar Investment Authority13G6.7%
Nov 3, 2026Qatar Investment Authority13G6.7%

Questions about Aspen Neuroscience, Inc. (ASPE) stock

Are ASPE insiders buying or selling?

In the last 12 months, ASPE insiders reported 4 open-market purchases worth $35M and no sales. The latest trade was on Nov 2, 2026. See every trade.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.